nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A2—locus ceruleus—narcolepsy	0.305	0.306	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—narcolepsy	0.162	0.163	CbGeAlD
Lisdexamfetamine—SLC18A2—brainstem—narcolepsy	0.0642	0.0644	CbGeAlD
Lisdexamfetamine—SLC18A2—forebrain—narcolepsy	0.0619	0.0621	CbGeAlD
Lisdexamfetamine—SLC6A3—brainstem—narcolepsy	0.0485	0.0487	CbGeAlD
Lisdexamfetamine—SLC6A3—forebrain—narcolepsy	0.0469	0.047	CbGeAlD
Lisdexamfetamine—SLC18A2—medulla oblongata—narcolepsy	0.0448	0.0449	CbGeAlD
Lisdexamfetamine—SLC18A2—midbrain—narcolepsy	0.0409	0.041	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—narcolepsy	0.0392	0.0393	CbGeAlD
Lisdexamfetamine—SLC6A2—forebrain—narcolepsy	0.0378	0.0379	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—narcolepsy	0.0309	0.031	CbGeAlD
Lisdexamfetamine—SLC6A2—medulla oblongata—narcolepsy	0.0273	0.0274	CbGeAlD
Lisdexamfetamine—ADRA1B—brain—narcolepsy	0.026	0.026	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—narcolepsy	0.0257	0.0258	CbGeAlD
Lisdexamfetamine—SLC6A3—brain—narcolepsy	0.0194	0.0195	CbGeAlD
Lisdexamfetamine—SLC6A2—brain—narcolepsy	0.0157	0.0157	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—HRH3—narcolepsy	0.00025	0.0754	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—HRH3—narcolepsy	0.000222	0.0668	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HRH3—narcolepsy	0.000158	0.0477	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CPT1B—narcolepsy	0.000148	0.0445	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—narcolepsy	9.39e-05	0.0283	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HCRTR2—narcolepsy	8.62e-05	0.026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HCRTR1—narcolepsy	8.62e-05	0.026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—P2RY11—narcolepsy	8.32e-05	0.0251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—narcolepsy	7.89e-05	0.0238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR2—narcolepsy	7.71e-05	0.0232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR1—narcolepsy	7.71e-05	0.0232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—P2RY11—narcolepsy	7.44e-05	0.0224	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HCRT—narcolepsy	7.08e-05	0.0213	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	6.66e-05	0.0201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	6.66e-05	0.0201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	6.43e-05	0.0194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HCRT—narcolepsy	6.33e-05	0.0191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	5.71e-05	0.0172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	5.71e-05	0.0172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	5.51e-05	0.0166	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—narcolepsy	5.36e-05	0.0162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—TRH—narcolepsy	5.36e-05	0.0162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—narcolepsy	4.8e-05	0.0145	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—narcolepsy	4.75e-05	0.0143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	4.69e-05	0.0141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HCRTR2—narcolepsy	4.35e-05	0.0131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HCRTR1—narcolepsy	4.35e-05	0.0131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—P2RY11—narcolepsy	4.2e-05	0.0127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	4.18e-05	0.0126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—TAC1—narcolepsy	3.9e-05	0.0117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—NPS—narcolepsy	3.9e-05	0.0117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	3.63e-05	0.011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HCRT—narcolepsy	3.57e-05	0.0108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	3.55e-05	0.0107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—narcolepsy	3.48e-05	0.0105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—narcolepsy	3.48e-05	0.0105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PENK—narcolepsy	3.18e-05	0.00959	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	3.11e-05	0.00939	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—TRH—narcolepsy	2.7e-05	0.00815	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	2.58e-05	0.00778	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	2.58e-05	0.00778	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HCRTR1—narcolepsy	2.46e-05	0.0074	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HCRTR2—narcolepsy	2.46e-05	0.0074	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—P2RY11—narcolepsy	2.37e-05	0.00715	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HRH3—narcolepsy	2.37e-05	0.00715	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—narcolepsy	2.34e-05	0.00707	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HCRTR1—narcolepsy	2.23e-05	0.00672	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HCRTR2—narcolepsy	2.23e-05	0.00672	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—P2RY11—narcolepsy	2.15e-05	0.00649	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—narcolepsy	2.1e-05	0.00632	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HCRT—narcolepsy	2.02e-05	0.00608	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—TAC1—narcolepsy	1.96e-05	0.00592	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPS—narcolepsy	1.96e-05	0.00592	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HCRT—narcolepsy	1.83e-05	0.00552	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	1.81e-05	0.00546	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PENK—narcolepsy	1.8e-05	0.00542	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PENK—narcolepsy	1.63e-05	0.00492	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	1.55e-05	0.00468	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRH—narcolepsy	1.53e-05	0.00461	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRH—narcolepsy	1.39e-05	0.00418	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HRH3—narcolepsy	1.34e-05	0.00404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HCRTR2—narcolepsy	1.32e-05	0.00397	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HCRTR1—narcolepsy	1.32e-05	0.00397	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—P2RY11—narcolepsy	1.27e-05	0.00383	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRH3—narcolepsy	1.22e-05	0.00367	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—narcolepsy	1.18e-05	0.00356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TAC1—narcolepsy	1.11e-05	0.00335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPS—narcolepsy	1.11e-05	0.00335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HCRT—narcolepsy	1.08e-05	0.00326	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TAC1—narcolepsy	1.01e-05	0.00304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPS—narcolepsy	1.01e-05	0.00304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PENK—narcolepsy	9.64e-06	0.00291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRH—narcolepsy	8.2e-06	0.00247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRH3—narcolepsy	7.19e-06	0.00217	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—narcolepsy	6.68e-06	0.00201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—narcolepsy	6.07e-06	0.00183	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPS—narcolepsy	5.96e-06	0.0018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TAC1—narcolepsy	5.96e-06	0.0018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—narcolepsy	3.58e-06	0.00108	CbGpPWpGaD
